Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameAbbisko-B
Stock Code02256
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們為一家臨床階段的生物製藥公司,致力於發現及開發創新且差異化的小分子腫瘤療法,已開發由14個專注於腫瘤學的候選藥物組成的管線,包括五種處於臨床階段的候選藥物。
Listing Date2021-10-13
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市浦東新區張江高科技園區哈雷路898號3號樓
Business Address (Hong Kong)香港灣仔皇后大道東248號大新金融中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.abbisko.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 12.46 / shares
Offer Price RangeFinal offer price only, no range
Lot Size2,000 shares
Entry ThresholdHK$ 24,920
Par ValueTo be extracted
Offer Period2021-09-30 to 2021-10-06
Global Offering Shares140,736,000 shares
HK Public Offer Shares (Initial)14,076,000 shares (10.0%)
Public Offer Lots (Initial)7,038lots (Pool A3,519lots,Pool B3,519lots)
International Placing Shares (Initial)126,660,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO702,466,350 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share56.6%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,753,570,560

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 2,000 HK$ 24,920
2 lots 4,000 HK$ 49,840
3 lots 6,000 HK$ 74,760
4 lots 8,000 HK$ 99,680
5 lots 10,000 HK$ 124,600
6 lots 12,000 HK$ 149,520
7 lots 14,000 HK$ 174,440
8 lots 16,000 HK$ 199,360
9 lots 18,000 HK$ 224,280
10 lots 20,000 HK$ 249,200
15 lots 30,000 HK$ 373,800
20 lots 40,000 HK$ 498,400
25 lots 50,000 HK$ 623,000
30 lots 60,000 HK$ 747,600
35 lots 70,000 HK$ 872,200
40 lots 80,000 HK$ 996,800
45 lots 90,000 HK$ 1,121,400
50 lots 100,000 HK$ 1,246,000
60 lots 120,000 HK$ 1,495,200
70 lots 140,000 HK$ 1,744,400
80 lots 160,000 HK$ 1,993,600
100 lots 200,000 HK$ 2,492,000
110 lots 220,000 HK$ 2,741,200
120 lots 240,000 HK$ 2,990,400
130 lots 260,000 HK$ 3,239,600
140 lots 280,000 HK$ 3,488,800
150 lots 300,000 HK$ 3,738,000
175 lots 350,000 HK$ 4,361,000
200 lots 400,000 HK$ 4,984,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
225 lots 450,000 HK$ 5,607,000
250 lots 500,000 HK$ 6,230,000
350 lots 700,000 HK$ 8,722,000
400 lots 800,000 HK$ 9,968,000
500 lots 1,000,000 HK$ 12,460,000
1,000 lots 2,000,000 HK$ 24,920,000
3,519 lots 7,038,000 HK$ 87,693,480

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 7.23B
Est. Threshold HK$ 9.37B
Analysis Result HK market cap below threshold, need +30%

Valuation & Financials

Market Cap (at Offer Price)HK$ 8,647,360,769
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status2020年度亏损人民币706.6百万元
Period-End Cash Balance人民币617.8百万元
Listing Expenses~HK$ 147,360,160
Listing Expenses / Funds Raised~8.4%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20192020
Other income and gains, net 12,70518,831
Administrative expenses -21,891-21,168
Operating profit -133,389-706,301
Net finance costs -523-338
Profit before tax -133,912-706,639
Income tax expense 00
Profit for the year -133,912-706,639
Balance Sheet
Item 20192020
Cash and cash equivalents 285,637617,773
Total current assets 300,181649,802
Total assets 320,236665,971
Total current liabilities 17,75031,749
Total liabilities 779,2611,770,959
Total equity -459,025-1,104,988
Equity attributable to owners -459,025-1,104,988
Cash Flow Statement
Item 201920202021-03
Net cash from operating activities -82,817-117,562
Net cash from investing activities 30,127-11,246
Net cash from financing activities 176,922505,890
Net increase in cash 124,232377,082
Depreciation of PP&E 3,1083,4821,210
Depreciation of right-of-use assets 5,0865,8711,468
Amortisation of intangible assets 0138100
Purchase of PP&E -3,435-3,462-765
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseLoading...
First Day OpenHK$ 11.30
First Day Change-13.56%
Use of Proceeds
1、將撥付約19.7%或316.2百萬港元用于進行中的及未來的研發; 2、將撥付約32.6%或523.2百萬港元用于進行中的及未來的研發; 3、將撥付約28.0%或449.4百萬港元用于我們的其他臨床階段產品及我們管線的候選產品; 4、將撥付約8.4%或134.8百萬港元用于我們的臨床前研究,包括持續開發我們的研發平臺及研發新型臨床前候選藥物; 5、將撥付約6.3%或101.1百萬港元用于建造上海的生產設施; 6、約5.0%或80.3百萬港元將用作我們的營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Far East) Limited CE AAB026
Overall Coordinators (3)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (7)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 中国国际金融香港证券有限公司 CE AEN894 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 海通国际证券有限公司 CE AAF806 香港上海汇丰银行有限公司 CE AAA523 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Lead Managers (7)
Morgan Stanley Asia Limited CE AAD291 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 中国国际金融香港证券有限公司 CE AEN894 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 海通国际证券有限公司 CE AAF806 香港上海汇丰银行有限公司 CE AAA523 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 AIHC Master Fund 46,550,560 HKD — 2.65% — 6 months 2022-04-13
2 Aranda Investments Pte. Ltd. 77,575,960 HKD — 4.42% — 6 months 2022-04-13
3 BlackRock Funds 77,575,960 HKD — 4.42% — 6 months 2022-04-13
4 Epsomite Gem Investments Ltd 116,376,400 HKD — 6.64% — 6 months 2022-04-13
5 Hudson Bay Master Fund LTD 77,575,960 HKD — 4.42% — 6 months 2022-04-13
6 Janchor Partners Pan-Asian Master Fund 54,300,680 HKD — 3.10% — 6 months 2022-04-13
7 Lake Bleu Prime Healthcare Master Fund Limited 77,575,960 HKD — 4.42% — 6 months 2022-04-13
8 LAV Star Limited 155,176,840 HKD — 8.85% — 6 months 2022-04-13
9 OrbiMed Funds 77,575,960 HKD — 4.42% — 6 months 2022-04-13
10 UBS Asset Management (Singapore) Ltd. 155,176,840 HKD — 8.85% — 6 months 2022-04-13
11 Vivo Funds 77,575,960 HKD — 4.42% — 6 months 2022-04-13

Directors & Management

PositionChinese nameEnglish Name
Chairman徐耀昌—
Company Secretary田慧敏、陳燕華—
No director data available.

Major Shareholders

Major Shareholders & Holdings徐耀昌、喻紅平、陳椎(一致行動人士)合共持有164,581,300股股份,佔緊隨全球發售完成後約23.43%(假設超額配股權未獲行使);施毅透過LAV實體持有約10.72%。
About this page

This page shows Abbisko-B (02256) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect